{"title":"与心脏移植后癌症发病相关的条件:对335名受者的纵向研究","authors":"Fabian Patauner, Filomena Boccia, Silvia Masini, Giuliana Autiero, Raffaella Gallo, Lorenzo Bertolino, Irene Mattucci, Daniela Pinto, Roberto Andini, Cristiano Amarelli, Rosa Zampino, Emanuele Durante-Mangoni","doi":"10.1111/ctr.70243","DOIUrl":null,"url":null,"abstract":"<p>Cancer is among the major causes of death after heart transplant (HTx). Risk factors for cancer occurrence in this setting are not well established. This was a retrospective observational study of patients who underwent HTx between 2006 and 2019 and were followed up until May 2024. Clinical variables possibly associated with cancer were assessed with univariable and multivariable analyses. Survival analysis was carried out drawing Kaplan Meier curves and a Cox regression with time-varying covariates were performed to overcome the immortal-time-bias. Three-hundred-thirty-five HTx recipients were included, of whom 42 (12.5%) developed cancer after a median of 6.3 years. In univariable analysis, older age at HTx, smoking history, alcohol use, male sex, ischemic heart disease before HTx, use of cyclosporine rather than tacrolimus, and increased length of follow-up were associated with cancer. Upon multivariable analysis, ischemic heart disease (OR 2.70 [1.19–6.11], <i>p</i> = 0.017) and length of follow-up (OR 1.02 [1.00–1.04], <i>p</i> = 0.007) were independently associated with cancer occurrence. Cox regression revealed a higher risk of mortality among patients with cancer (HR 3.400, [2.026–5.709], <i>p</i> < 0.001). HTx recipients with prior ischemic cardiomyopathy and a longer survival time after transplant show a higher risk of developing cancer. Cancer significantly impairs post-transplant survival.</p>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 8","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ctr.70243","citationCount":"0","resultStr":"{\"title\":\"Conditions Associated With the Onset of Cancer After Heart Transplant: Longitudinal Study in 335 Recipients\",\"authors\":\"Fabian Patauner, Filomena Boccia, Silvia Masini, Giuliana Autiero, Raffaella Gallo, Lorenzo Bertolino, Irene Mattucci, Daniela Pinto, Roberto Andini, Cristiano Amarelli, Rosa Zampino, Emanuele Durante-Mangoni\",\"doi\":\"10.1111/ctr.70243\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Cancer is among the major causes of death after heart transplant (HTx). Risk factors for cancer occurrence in this setting are not well established. This was a retrospective observational study of patients who underwent HTx between 2006 and 2019 and were followed up until May 2024. Clinical variables possibly associated with cancer were assessed with univariable and multivariable analyses. Survival analysis was carried out drawing Kaplan Meier curves and a Cox regression with time-varying covariates were performed to overcome the immortal-time-bias. Three-hundred-thirty-five HTx recipients were included, of whom 42 (12.5%) developed cancer after a median of 6.3 years. In univariable analysis, older age at HTx, smoking history, alcohol use, male sex, ischemic heart disease before HTx, use of cyclosporine rather than tacrolimus, and increased length of follow-up were associated with cancer. Upon multivariable analysis, ischemic heart disease (OR 2.70 [1.19–6.11], <i>p</i> = 0.017) and length of follow-up (OR 1.02 [1.00–1.04], <i>p</i> = 0.007) were independently associated with cancer occurrence. Cox regression revealed a higher risk of mortality among patients with cancer (HR 3.400, [2.026–5.709], <i>p</i> < 0.001). HTx recipients with prior ischemic cardiomyopathy and a longer survival time after transplant show a higher risk of developing cancer. Cancer significantly impairs post-transplant survival.</p>\",\"PeriodicalId\":10467,\"journal\":{\"name\":\"Clinical Transplantation\",\"volume\":\"39 8\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ctr.70243\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70243\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70243","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
摘要
癌症是心脏移植后死亡的主要原因之一。在这种情况下发生癌症的危险因素尚未得到很好的确定。这是一项回顾性观察研究,研究对象是2006年至2019年期间接受HTx治疗的患者,随访至2024年5月。通过单变量和多变量分析评估可能与癌症相关的临床变量。绘制Kaplan Meier曲线进行生存分析,并采用时变协变量Cox回归克服不朽的时间偏差。纳入335名HTx接受者,其中42名(12.5%)在中位6.3年后患上癌症。在单变量分析中,HTx时年龄较大、吸烟史、饮酒、男性、HTx前缺血性心脏病、使用环孢素而非他克莫司、随访时间延长与癌症相关。多变量分析显示,缺血性心脏病(OR 2.70 [1.19-6.11], p = 0.017)和随访时间(OR 1.02 [1.00-1.04], p = 0.007)与癌症发生独立相关。Cox回归分析显示,癌症患者死亡风险较高(HR 3.400, [2.026-5.709], p <;0.001)。先前有缺血性心肌病和移植后生存时间较长的HTx受者患癌症的风险较高。癌症显著损害移植后的生存。
Conditions Associated With the Onset of Cancer After Heart Transplant: Longitudinal Study in 335 Recipients
Cancer is among the major causes of death after heart transplant (HTx). Risk factors for cancer occurrence in this setting are not well established. This was a retrospective observational study of patients who underwent HTx between 2006 and 2019 and were followed up until May 2024. Clinical variables possibly associated with cancer were assessed with univariable and multivariable analyses. Survival analysis was carried out drawing Kaplan Meier curves and a Cox regression with time-varying covariates were performed to overcome the immortal-time-bias. Three-hundred-thirty-five HTx recipients were included, of whom 42 (12.5%) developed cancer after a median of 6.3 years. In univariable analysis, older age at HTx, smoking history, alcohol use, male sex, ischemic heart disease before HTx, use of cyclosporine rather than tacrolimus, and increased length of follow-up were associated with cancer. Upon multivariable analysis, ischemic heart disease (OR 2.70 [1.19–6.11], p = 0.017) and length of follow-up (OR 1.02 [1.00–1.04], p = 0.007) were independently associated with cancer occurrence. Cox regression revealed a higher risk of mortality among patients with cancer (HR 3.400, [2.026–5.709], p < 0.001). HTx recipients with prior ischemic cardiomyopathy and a longer survival time after transplant show a higher risk of developing cancer. Cancer significantly impairs post-transplant survival.
期刊介绍:
Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include:
Immunology and immunosuppression;
Patient preparation;
Social, ethical, and psychological issues;
Complications, short- and long-term results;
Artificial organs;
Donation and preservation of organ and tissue;
Translational studies;
Advances in tissue typing;
Updates on transplant pathology;.
Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries.
Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.